Avastin MCRC Pivotal Trials

If granted approval, fruquintinib will be the first and only highly selective inhibitor of all 3 VEGF receptors to be approved in the United States for patients with metastatic colorectal cancer.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

In an interview with Targeted Oncology, Siamak Daneshmand, MD, discussed TAR-200 as seen in the SunRISE-1 trial and the what is up next for the treatment landscape of high-risk BCG-unresponsive non-muscle invasive bladder cancer.

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD.

In an interview with Targeted Oncology, Craig Horbinski, MD, PhD, discussed recent recommendations and NCCN guidelines regarding the molecular profiling of gliomas and other central nervous system cancers.